Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic EGFR CLIA Test

Transgenomic has launched its new CLIA laboratory-based test for EGFR mutation detection in cancer patients using proprietary MX-ICP technology with any sample type.

The test is for EGFR exon 20 T790M mutations that affect the utility of tyrosine kinase inhibitor drugs for non-small cell lung cancer and EGFR exon 12 S492R mutations that signify resistance to the widely-prescribed drug cetuximab in coloretal cancer patients. 

The test can use tissue, plasma, fine needle aspiration, bronchoscopy, cytology, and other bodily fluid samples. Actionable results will be available in seven to 10 working days, Transgenomic said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.